Coya Therapeutics Reports $10.6 Million Q3 Net Loss; ALSTARS Enrollment Complete
Coya Therapeutics reported a Q3 2026 net loss of $10.6M, up from $2.1M a year earlier, due to increased R&D costs. Collaboration revenue was $234K, down from $3.6M. The company has $35.8M in cash and expects funding to last into 2H 2027. Enrollment in the Phase 2/3 ALSTARS trial is complete, with topline results expected in early Q2 2027.
How this was made
The 30-second read
Why it matters
The Q3 loss and cash position raise near‑term valuation concerns, but the completed enrollment may set up a pivotal data readout in 2027.
Market read
Earnings release provides fresh data for investors; likely short‑term price pressure but long‑term upside if trial data are positive.
What to watch
Potential future funding from partners or grants not disclosed may mitigate cash concerns.
Background
Coya Therapeutics is a clinical‑stage biotech focused on ALS therapies. The ALSTARS trial is its lead program.
Ticker impact
Coya Therapeutics reported a Q3 2026 net loss of $10.6M, cash of $35.8M, and completed enrollment in its Phase 2/3 ALSTARS ALS trial.
likely pressure as investors price in higher loss and cash consumption
Losses widened year‑over‑year and cash is limited; biotech stocks often react negatively to disappointing earnings absent new data.
Market effects
Biotech sector may see modest downside pressure as earnings highlight cash constraints.
U.S. small‑cap biotech investors may adjust exposure.
Limited; impact confined to niche biotech investors.
Counterpoint
The trial enrollment completion could be a catalyst that outweighs short‑term earnings disappointment.
Key entities
- companyCoya Therapeutics
Clinical‑stage biotech developing ALS therapy COYA 302.